InvestorsHub Logo

The Irishman

05/22/20 10:28 AM

#275510 RE: eightisenough #275498

thank you for your comments. I do appreciate them. You might be right. However, I don’t believe that supply is a major consideration of the FDA with this generic. Nevertheless, we will see what real meaning this will all have soon enough.

Hikma making a go for it? Very few do manufacturer at risk, very few. Yet, in the case of Amarin, nothing is what it seems.

Be well my friend and enjoy your weekend as well.

moonotaur

05/22/20 10:49 AM

#275519 RE: eightisenough #275498

What are the grounds for settlement? Why would amarin settle at this point? Amarin needs to see the appeal through to get their IP back. If they settle that doesn’t happen.

I could see the generics wanting to work something out to hedge their risk at an overturn on appeal, but again why would amarin accept? Pay a large amount of money or revenue based royalty? For what, so hikma/Dr. reddy’s stands down for a few years? There’s already another generic pounding at the door.

A settlement is a pipe dream. Not going to happen.